BerGenBio

Report Publication Announcement • Aug 10, 2020

BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation

BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation

Bergen, Norway, 10 August 2020 - BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

unmet medical need, will be announcing its results for the second quarter 2020

on Tuesday 18 August 2020. A webcast presentation by BerGenBio's senior

management team will take place at 10:00 am CET.

The live webcast link will be available at www.bergenbio.com in the

Investors/Financial Reports section. A recording will be available shortly after

the webcast has finished.

The second quarter report and presentation will be available on the Company's

website in the Investors/Financial Reports section from 7:00 am CET the same

day.

-Ends-

Contacts

Richard Godfrey CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs,

Consilium Strategic Communications

bergenbio@consilium-comms.com

+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no

+47 995 13 891

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive and therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad Phase II oncology clinical development

programme focused on combination and single agent therapy in lung cancer,

leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,

tilvestamab, is undergoing Phase I clinical testing. In parallel, BerGenBio is

developing companion diagnostic tests to identify those patient populations most

likely to benefit from bemcentinib or tilvestamab: this is expected to

facilitate more efficient registration trials and support a precision medicine

-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO).

For further information, please visit:

www.bergenbio.com (http://www.bergenbio.com)